4 results on '"Myf-6"'
Search Results
2. Promoting and accelerating muscle regeneration through cell therapy in a mouse model
- Author
-
Marwa I. Salman, PhD, Eman G. Khalil, PhD, Aous K. Almzaien, MSc, Ali A. Hadi, PhD, Aysar A. Ahmed, BSc, Hiba K. Shaker, BSc, and Ahmed M. Al-Shammari, PhD
- Subjects
Cellular therapy ,MSCs ,Myf-6 ,SEM ,Skeletal muscle ,Medicine (General) ,R5-920 - Abstract
الملخص: أهداف البحث: تعد إصابات واضطرابات العضلات الهيكلية تحديات سريرية عالمية ذات آليات مباشرة وغير مباشرة وتأثيرات متبقية ملحوظة، مثل الألم الشديد الذي يستمر لفترة طويلة والإعاقة الجسدية. الخلايا الجذعية هي أداة مبتكرة للعلاج بالخلايا ضد الاضطرابات العضلية الهيكلية والتي يمكن أن تعزز على وجه التحديد تجديد العضلات والهيكل العظمي. تهدف الدراسة الحالية إلى دراسة استخدام الخلايا الجذعية الوسيطة وخلاياها العضلية المتمايزة لإعادة بناء العضلات الهيكلية التالفة أو المريضة كعلاج قائم على الخلايا لتعزيز تجديد العضلات. طريقة البحث: تم عزل الخلايا الجذعية الوسيطة للنخاع العظمي من النخاع العظمي للفئران البالغة وتم تربيتها في رقائق زراعة الأنسجة. كانت الخلايا الجذعية الوسيطة للنخاع العظمي إيجابية لـ سي د 90 و سي دي 105، وسالبة لـ سي دي 45 و سي دي 34. تم تحفيز هذه الخلايا في المختبر إلى سلالة خلايا عضلية هيكلية من خلال وسط تمايز محدد في 7 أيام. تم توصيف تمايز العضلات الهيكلية عن طريق صبغة الهيماتوكسيلين والأيوسين وفحصها عن طريق المسح المجهري الإلكتروني لدراسة التشكل. تم إجراء الصبغ المناعي لـ العامل العضلي 6، وسلسلة الميوسين الثقيلة، وعوامل محددة لتطور العضلات الهيكلية، لتأكيد تمايز العضلات الهيكلية. في دراسة على الجسم الحي، تم إنشاء نموذج إصابة العضلات الذي يستخدم لتقييم العلاج بالخلايا باستخدام الخلايا الجذعية الساذجة والخلايا العضلية المتمايزة. النتائج: لقد أثبتنا أن الفئران المستزرعة أن الخلايا الجذعية الوسيطة للنخاع العظمي كانت إيجابية بالنسبة لـ سي د 90 و سي دي 105، وسلبية بالنسبة لـ سي دي 45 و سي دي 34. تم تطوير هذه الخلايا إلى عضلات هيكلية تظهر إمكانات تمايز قوية للعضلات الهيكلية تم تأكيدها بشكل فعال بواسطة الكيمياء المناعية لعلامات العامل العضلي 6 وسلسلة الميوسين الثقيلة وديزمين. أظهرت الخلايا العضلية المتمايزة تعزيزا أفضل للإصلاح من الخلايا الجذعية غير المتمايزة عند زرعها في نموذج فأر لعلاج ضمور العضلات الهيكلية. الاستنتاجات: يمكن تضمين الخلايا العضلية المشتقة من الخلايا الجذعية الوسيطة للنخاع العظمي في علاج ضمور العضلات كاستراتيجية بيولوجية لإدارة أمراض وإصابات العضلات الهيكلية من أجل تطوير العلاجات السريرية القائمة على الخلايا. Abstract: Objectives: Skeletal muscle injuries and disorders are universal clinical challenges with direct and indirect mechanisms and notable residual effects, such as prolonged, intense pain and physical disability. Stem cells, an innovative tool for cell therapy for musculoskeletal disorders, specifically promote skeletal muscle regeneration. This study was aimed at investigating the use of mesenchymal stem cells (MSCs) and their differentiated myocytes as a cell-based therapy to promote regeneration in damaged or diseased skeletal muscle. Methods: Bone marrow mesenchymal stem cells (BM-MSCs) were isolated from the bone marrow of adult mice and grown in tissue culture flasks. The BM-MSCs were positive for CD90 and CD105, and negative for CD45 and CD34. These cells were induced with specific differentiation medium in vitro to differentiate into a skeletal muscle cell lineage over 7 days. Skeletal muscle differentiation was characterized according to morphology through hematoxylin and eosin staining, and scanning electron microscopy. Immunostaining for Myf-6, myosin heavy chain (MHC), and desmin—specific factors for skeletal muscle development—was performed to confirm skeletal muscle differentiation. An in vivo study in a muscle injury model was used to evaluate cell therapy based on naïve stem cells and differentiated myocytes. Results: Cultured mouse BM-MSCS were positive for CD90 and CD105, and negative for CD45 and CD34. These cells developed into skeletal muscle with strong skeletal muscle differentiation potential, as confirmed by immunohistochemistry for the markers Myf6, MHC, and desmin. The differentiated myocytes showed better repair enhancement than undifferentiated stem cells after transplantations into a mouse model of skeletal muscle atrophy. Conclusions: Myocytes derived from BM-MSCs may be incorporated into muscular atrophy treatment as a biological strategy for managing skeletal muscle diseases and injuries, thus advancing cell-based clinical treatments.
- Published
- 2024
- Full Text
- View/download PDF
3. Myogenic protein expression before and after resistance loading in 26- and 64-yr-old men and women.
- Author
-
Bamman, Marcas M., Ragan, Ronald C., Jeong-su Kim, Cross, James M., Hill, Vernishia J., Tuggle, S. Craig, and Allman, Richard M.
- Subjects
PROTEINS ,CYCLINS ,OLDER people ,CELL cycle ,EXERCISE ,BIOPSY - Abstract
Based on the growing body of evidence implicating an important role for myogenic regulatory factors (MRFs) in the adaptive responses of skeletal muscle to mechanical load, we tested the hypothesis that protein concentrations of MRFs as well as cell cycle proteins (i.e., cyclins and cyclin-dependent kinase inhibitors) would be altered after heavy leg resistance exercise (RE). Because we and others, however, have shown a blunted adaptive response to long-term resistance training in older (O) women [females (F)] compared with men (M), we also tested the hypothesis that these myogenic responses to RE would be influenced by age and gender. Twenty-two younger (Y) adults (20-35 yr, 11 YF, 11 YM) and 20 O adults (60-75 yr, 9 OF, 11 OM) consented to vastus lateralis muscle biopsy before and 24 h after a bout of RE using a regimen known to induce myofiber hypertrophy when performed 2-3 days/wk for several weeks (3 sets of 80% one-repetition maximum for squat, leg press, and knee extension). Protein concentrations of MRFs (MyoD, myogenin, myf-6), cyclin D1, cyclin B1, α-actin, and the cyclindependent kinase inhibitor p27
kip were determined by immunoblotting. Data were analyzed by using age × gender × load repeated measures ANOVA. Myogenin expression was 44% higher (P < 0.05) in O compared with Y, and myf-6 tended to be higher in OF compared with YF (95%, P = 0.059). A significant gender × load interaction indicated that, in F, RE led to a reduction in p27kip (20%; P < 0.05), which was driven mainly by a 27% drop in OF. Levels of cyclin D1, cyclin B1, MyoD, myf-6, and α-actin were not influenced by age, gender, or loading. We report a novel finding in humans of markedly higher myogenin protein content in older sedentary muscle. The results do not, however, support the hypothesis that myogenic protein expression is altered 24 h after RE, irrespective of age or gender. Although the time point of postexercise muscle biopsy could be viewed as too early to capture maximal effects for most of these proteins, the significant decline in p27kip concentration found in OF suggests that mechanical load may provide one means of overcoming the inhibitory influence of p27kip . [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
4. The muscle regulatory gene, Myf-6, has a biphasic pattern of expression during early mouse development
- Author
-
H.H. Arnold, Eva Bober, Thomas Braun, Margaret Buckingham, G Cossu, G E Lyons, and Publica
- Subjects
muscle ,Population ,Molecular Sequence Data ,Muscle Proteins ,muscle protein ,Biology ,Muscle Development ,regulator gene ,Gene expression ,Genes, Regulator ,medicine ,Humans ,Northern blot ,education ,gene ,Myogenin ,Regulation of gene expression ,education.field_of_study ,Base Sequence ,Muscles ,Skeletal muscle ,Nucleic Acid Hybridization ,regulation ,Cell Biology ,Articles ,DNA ,Blotting, Northern ,Molecular biology ,Cell biology ,medicine.anatomical_structure ,Gene Expression Regulation ,Myogenic Regulatory Factors ,Myogenic regulatory factors ,gene expression ,MYF6 ,Myf-6 - Abstract
The spatial and temporal expression pattern of the muscle regulatory gene Myf-6 (MRF4/herculin) has been investigated by in situ hybridization during embryonic and fetal mouse development. Here, we report that the Myf-6 gene shows a biphasic pattern of expression. Myf-6 transcripts are first detected in the most rostral somites of the mouse embryo at 9 d of gestation and accumulate progressively in myotomal cells along the rostro-caudal axis. This expression is transient and Myf-6 mRNA can no longer be detected in myotomal cells after day 12 post coitum (p.c.). In contrast to other muscle determination genes (MyoD1, myogenin, Myf-5), Myf-6 mRNA is not detected in limb buds or visceral arches and skeletal muscle of the mouse embryo (day 8-15 p.c.). In fetal mice, Myf-6 transcripts appear at day 16 p.c. in all skeletal muscles, and the gene continues to be expressed at a high level after birth. These results suggest that early Myf-6 expression may be restricted to a population of myogenic cells that does not contribute to the embryonic muscle masses in limb buds and visceral arches. The reappearance of Myf-6 mRNA in fetal skeletal muscle coincides approximately with secondary muscle fiber formation and the onset of innervation.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.